PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System.
bone marrow
bowel
cervical cancer
chemoradiotherapy
dose reduction
proton therapy
quality of life
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Oct 2021
15 Oct 2021
Historique:
received:
31
08
2021
revised:
01
10
2021
accepted:
11
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a very effective treatment for locally advanced cervical cancer (LACC). However, treatment-related toxicity is common and reduces the patient's quality of life (QoL) and ability to complete treatment or undergo adjuvant therapies. Intensity modulated proton therapy (IMPT) enables a significant dose reduction in organs at risk (OAR), when compared to that of standard intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). However, clinical studies evaluating whether IMPT consequently reduces side effects for LACC are lacking. The PROTECT trial is a nonrandomized prospective multicenter phase-II-trial comparing clinical outcomes after IMPT or IMRT/VMAT in LACC. Thirty women aged >18 years with a histological diagnosis of LACC will be included in either the IMPT or IMRT/VMAT group. Treatment includes EBRT (45 Gy in 25 fractions of 1.8 Gy), concurrent five weekly cisplatin (40 mg/m
Identifiants
pubmed: 34680328
pii: cancers13205179
doi: 10.3390/cancers13205179
pmc: PMC8533850
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Varian Medical Systems
ID : 2019008
Références
Gynecol Oncol. 2014 Nov;135(2):231-8
pubmed: 25172763
Radiother Oncol. 2018 Jun;127(3):423-430
pubmed: 29784450
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):181-189
pubmed: 26372435
Radiother Oncol. 2021 Jan;154:194-200
pubmed: 32956707
Int J Part Ther. 2018 Winter;4(3):1-11
pubmed: 31773009
Cancers (Basel). 2021 Apr 14;13(8):
pubmed: 33919905
Gynecol Oncol. 2017 Nov;147(2):439-449
pubmed: 28830646
Virchows Arch. 2018 Jun;472(6):919-936
pubmed: 29725757
Eur J Cancer. 2021 Jul;151:159-167
pubmed: 33993062
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65
pubmed: 16757127
Lancet Oncol. 2021 Apr;22(4):538-547
pubmed: 33794207
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1088-98
pubmed: 26876955
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer. 1991 Jul 1;68(1):79-83
pubmed: 1904794
Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1032-1039
pubmed: 28332986
Radiother Oncol. 2017 Aug;124(2):296-301
pubmed: 28739383
Cancer. 2016 May 15;122(10):1483-501
pubmed: 26828647
Oncoimmunology. 2016 Dec 23;6(2):e1267095
pubmed: 28344877
Radiother Oncol. 2013 Apr;107(1):69-74
pubmed: 23639580
Radiat Oncol. 2020 Jul 29;15(1):180
pubmed: 32727497
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):800-7
pubmed: 20400238
Biomed Res Int. 2014;2014:143020
pubmed: 25136554
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S101-7
pubmed: 20171503
Int J Gynecol Cancer. 2016 May;26(4):770-6
pubmed: 26844613
Int J Gynecol Cancer. 2019 Feb;29(2):257-265
pubmed: 30630883
Radiat Oncol. 2017 Nov 28;12(1):188
pubmed: 29179751
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):673-9
pubmed: 25151538
Radiother Oncol. 2021 Sep 21;164:128-137
pubmed: 34560187
Acta Oncol. 2015;54(9):1567-73
pubmed: 26271799
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1265-71
pubmed: 12654436
Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):49-60
pubmed: 8380147
Radiother Oncol. 2016 Sep;120(3):397-403
pubmed: 27452411
Acta Oncol. 2016 Nov;55(11):1257-1265
pubmed: 27500710